Pfizer Attempts to Exit EpiPen Anticompetitive Suit

Pfizer wants out of a consumer class-action lawsuit involving Mylan and other drugmakers over generic EpiPen.

The companies are accused of anticompetitive behavior to keep generic versions of the EpiPen (epinephrine autoinjector) off the market.

The lawsuit in the U.S. District Court for Kansas alleges that Mylan engaged in illegal practices with Pfizer subsidiaries King Pharmaceuticals and Meridian Medical Technologies to monopolize the market.